Concurrent capecitabine radiosensitization (825 mg/m² PO BID on RT days only) — paired with conventionally fractionated GI chemoradiation
Visão determinística da entidade fonte YAML. A autoridade clínica permanece com os IDs de fonte citados e estado de assinatura do revisor.
Registro de base de conhecimento para auditoria. Conteúdo clínico provisório: não é uma prescrição. Um oncologista deve verificar fontes originais, aplicabilidade e estado de revisão. Regras completas e restrições estão no YAML.
| Componentes | DRUG-CAPECITABINE |
|---|
| ID | REG-CAPECITABINE-CRT-CONCURRENT |
|---|---|
| Tipo | Esquema terapêutico |
| Estado | reviewed 2026-05-08 | pending_clinical_signoff | actionability review required |
| Doenças | Nenhuma declaração |
| Fontes | SRC-ESMO-CRC-2024 SRC-NCCN-COLON-2025 SRC-NCCN-PANCREATIC-2025 SRC-PRODIGE-23-CONROY-2021 |
Notas
Concurrent radiosensitizing capecitabine paired with a conventionally fractionated GI RadiationCourse — distinct from the cyclic palliative capecitabine pattern (REG-CAPECITABINE-PALLIATIVE: 1000 mg/m² BID days 1-14 / 21d for ECOG 3-4 mCRC). The 825 mg/m² PO BID "on RT days only" schedule has no fixed cycle structure: capecitabine is taken Monday through Friday during each week of RT delivery (with the daily dose split BID, typically ~12 hours apart, ideally bracketing the RT fraction), held on weekends and any RT-off days, and stopped with the final RT fraction. Total exposure ~5.5 weeks for the canonical 50.4 Gy / 28 fx pairing. Authored to back-fill the `concurrent_chemo_regimen` FK on two §17 RadiationCourse entities that previously had to leave the field explicitly null with audit-trail comments because no matching regimen existed: - RC-LCCRT-504-28-RECTAL — long-course preoperative chemoradiation for locally advanced rectal cancer (PRODIGE-23 TNT CRT phase / standard arm; SRC-PRODIGE-23-CONROY-2021, SRC-NCCN-COLON-2025, SRC-ESMO-CRC-2024). Conroy 2021, Lancet Oncology n=461; 3-yr DFS 75.7% (TNT) vs 68.5% (standard); pCR 27.8% vs 12.1%. - RC-LAPC-CHEMORADIATION-PDAC — definit...
Usado por
Indicação
IND-PDAC-LAPC-CHEMORADIATION- IND-PDAC-LAPC-CHEMORADIATIONIND-RECTAL-TNT-LONG-COURSE-PRODIGE23- IND-RECTAL-TNT-LONG-COURSE-PRODIGE23
Cursos de Radiação
RC-LAPC-CHEMORADIATION-PDAC- Quimioterapia de consolidação definitiva para adenocarcinoma pancreático localmente avançado e irresecável (50,4 Gy / 28 fx)RC-LCCRT-504-28-RECTAL- Quimioterapia pré-operatória de longo curso para o cancro do recto (50.4 Gy / 28 fx + concomitante capecitabine)